NASDAQ · PHARMACEUTICAL PREPARATIONS
Connect Biopharma Holdings Ltd. CNTB
3 fiscal years on record · USD · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 64,000.00
Revenue, FY2025 · full 3-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.1 · Net income -55.5
10.0M20.0M-25.0M-50.0M
202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
ROE
FY2025 · ROE -82.7%
-50%
202320242025
Three returns, three denominators.
Each USD of equity lost 83 cents this year.
The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.0 | −0.1 |
| EBITDA $B | −0.1 | −0.0 | −0.1 |
| Income tax $B | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.0 | −0.1 |
| Free cash flow $B | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −1.00 | −0.28 | −1.13 |
| Dividend / sh $ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — |
| ROE % | −82.7 | −16.1 | −61.2 |
| Shares out B | 0.06 | 0.06 | 0.06 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 12 reconciliationsAUDITED
Reconciled in 3 of the 3 fiscal years we could check. 32 checks were skipped: the balance sheet is not tagged before 2023. 16 checks were skipped: EPS is not tagged before 2023.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2023